ICER

News

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

News

ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.

News

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

Digital

Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike.